Phase-II Clinical Trial of Drug Evizon for Wet Age-Related Macular Degeneration
Biopharmaceutical company Genaera Corporation has commenced a multi-center phase II clinical trial to explore the efficacy and safety of higher doses of its investigational drug Evizon for the treatment of the eye disease, wet age-related macular degeneration.
The study is designed to evaluate up to 140 patients with wet age-related macular degeneration (AMD) treated with Evizon at four dose levels of 40mg, 80mg, 120mg and 160mg over a 20 week period.
There is a significant medical need for a drug that treats wet AMD in both eyes simultaneously, while avoiding the complications of intravitreal injections.
Source: Pharmaceutical-Business-Review.
Filed under Eye Treatment, Macular Degeneration
You may also like to read
- Hope for Age Related Macular Degeneration with Lucentis
- Age-Related Macular Degeneration Can Be Avoided By Taking Nutrients
- Brand New Treatment For Macular Degeneration
- Age Related Macular Degeneration May be Prevented with Macugen
- Phase II Clinical Trial of Mifepristone an Eye Drop Treatment for Steroid Associated Elevated Intraocular Pressure
- Midwest Eye Institute Doctor Helps To Test Drug For Macular Degeneration
- Can-Fite Begins Phase II Trials for Treatment of Symptoms of Keratitis Sicca (Dry-Eye Syndrome)
- Lucentis - Wet Macular Degeneration Drug is Highly Successful in Clinical Trials
- Novagali eye Treatment for Vernal Keratoconjunctivitis (VKC) Successful in Phase III Trial
- Macular Degeneration and its New Treatments
